✦ LIBER ✦

PND11 NURSE COSTING SURVEY FOR THE MANAGEMENT OF ADVERSE EVENTS IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH DISEASE-MODIFYING DRUGS IN THE UK

✍ Scribed by R Perard; L Parkes

Book ID: 118614785
Publisher: John Wiley and Sons
Year: 2010
Tongue: English
Weight: 79 KB
Volume: 13
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(11)72592-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The UK patient experience of relapse in

The UK patient experience of relapse in Multiple Sclerosis treated with first disease modifying therapies

✍ Duddy, Martin; Lee, Martin; Pearson, Owen; Nikfekr, Esmaeil; Chaudhuri, Abhijit; 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 484 KB

PND61 Impact of Patient Cost-Sharing Arr

PND61 Impact of Patient Cost-Sharing Arrangements for Disease Modifying Therapies on Treatment Compliance among Patients with Multiple Sclerosis in the United States

✍ L.A. Palmer; R. Fowler; N. Shi; H. Dastani; S. Abouzaid; E. Kim 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

Newer disease-modifying antirheumatic dr

Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis

✍ Samy Suissa; Pierre Ernst; Marie Hudson; Alain Bitton; Abbas Kezouh 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 80 KB

Cost-Effectiveness Analyses of Natalizum

Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

✍ Gani, Ray; Giovannoni, Gavin; Bates, David; Kemball, Belinda; Hughes, Steve; Ker 📂 Article 📅 2008 🏛 Springer International Publishing AG 🌐 English ⚖ 133 KB

PRS28 COST-UTILITY ANALYSES OF DISEASE-M

PRS28 COST-UTILITY ANALYSES OF DISEASE-MODIFYING THERAPIES FOR PATIENTS WITH RELAPSE-REMITTING MULTIPLE SCLEROSIS IN THE UNITED STATE

✍ M Yang; WW Tseng; SS Sansgiry 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 76 KB

Consensus guidelines for the optimal man

Consensus guidelines for the optimal management of adverse events in newly diagnosed, transplant-ineligible patients receiving melphalan and prednisone in combination with thalidomide (MPT) for the treatment of multiple myeloma

✍ A. Palumbo; F. Davies; M. Kropff; J. Bladé; M. Delforge; F. Leal da Costa; R. Ga 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 206 KB